[ad_1]
San Diego, January 23, 2022 /PR Newswire/ — the law firm of Robbins Geller Rudman & Dodd LLP Announced NRx Pharmaceuticals, Inc. (NASDAQ:NRXP, NRXPW)) between June 1, 2021 and November 4, 2021, including two dates (“class period”) until March 21, 2022 Seeking appointment as lead plaintiff dalbosco v. NRx Pharmaceuticals, No. 22-cv-00066 (D. Del.).start with January 18, 2022, This NRx Pharmaceuticals The class action alleges that NRx and some of its senior executives violated the Securities Exchange Act of 1934.
If you have suffered a substantial loss and wish to be the lead plaintiff in this case NRx Pharmaceuticals class action, Please click here to provide your information. You can also contact a lawyer JC Sanchez Call 800/449-4900 or email Robbins Geller jsanchez@rgrdlaw.com. Lead Plaintiff’s Motion NRx Pharmaceuticals A class action must be brought to court no later than March 21, 2022.
case allegations: NRx is a clinical-stage small molecule pharmaceutical company developing a variety of therapies for the treatment of central nervous system disorders and life-threatening lung diseases. NRx’s products include ZYESAMI, an investigational pre-commercial drug for COVID-19-related respiratory failure.exist June 2021, NRx announced the submission of an application to the U.S….
The full story is available on Benzinga.com
[ad_2]
Source link
